Optinose rises as US FDA accepts chronic sinus treatment for review

OptiNose

04/05/2023 16:27

** Shares of drug developer Optinose Inc  OPTN.O  rise 8% to
$1.89 
    ** Co says the U.S. Food and Drug Administration (FDA)
accepted for review its supplemental application requesting
approval of its drug-device combination, Xhance, to treat
chronic sinusitis
    ** FDA will finalize its decision by Dec 16 - OPTN 
    ** Chronic sinusitis is a condition in which cavities around
nasal passages are inflamed and swollen for at least 12 weeks,
for which there are currently no FDA-approved treatments
    ** Xhance is already approved in the U.S. for treatment of
nasal polyps, a condition which causes swelling of the nasal
lining
    ** Including session's gain, stock up ~3% YTD 

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))